Street Calls of the Week
Kura Oncology NASDAQ:KURA Chief Operating Officer Kathleen Ford sold 6,892 shares of common stock on September 29, 2025, at a price of $8.9422, for a total value of $61,629. The transaction comes as the stock shows strong momentum, with a 10.9% gain over the past week and a 27.2% surge over six months. The sale was to cover taxes associated with the vesting of restricted stock units. Separately, on September 27, Ford acquired 48,900 shares at $0.
Following these transactions, Ford directly owns 63,375 shares of Kura Oncology. The company, currently valued at $777 million, maintains a strong financial position with more cash than debt and a healthy current ratio of 6.2. According to InvestingPro analysis, which offers 12 additional investment insights for this stock, Kura appears fairly valued based on its current Fair Value assessment.
In other recent news, Kura Oncology reported a significant miss in its Q2 2025 financial results. The company’s revenue was $15.3 million, falling short of the anticipated $39.1 million, a 60.88% shortfall. Earnings per share also disappointed, with a reported loss of $0.75 compared to the expected loss of $0.41. Following these results, Citizens JMP lowered its price target for Kura Oncology to $24.00 while maintaining a Market Outperform rating. Guggenheim initiated coverage of Kura Oncology with a Neutral rating, highlighting challenges in the upcoming launch of ziftomenib for AML due to competition. Additionally, Kura Oncology plans to present preliminary clinical data for its drug darlifarnib at an upcoming medical congress. Preclinical data for KO-2806, also known as darlifarnib, has shown promise in overcoming resistance to targeted therapies. These developments come as the company continues to focus on its pipeline and potential treatment advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.